FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2984520652> ?p ?o ?g. }

• W2984520652 endingPage "402" @default.
• W2984520652 startingPage "392" @default.
• W2984520652 abstract "Retinitis pigmentosa (RP) is the most common form of inherited vision loss and is characterized by degeneration of retinal photoreceptor cells and the retinal pigment epithelium (RPE). Mutations in pre-mRNA processing factor 31 (PRPF31) cause dominant RP via haploinsufficiency with incomplete penetrance. There is good evidence that the diverse severity of this disease is a result of differing levels of expression of the wild-type allele among patients. Thus, we hypothesize that PRPF31-related RP will be amenable to treatment by adeno-associated virus (AAV)-mediated gene augmentation therapy. To test this hypothesis, we used induced pluripotent stem cells (iPSCs) with mutations in PRPF31 and differentiated them into RPE cells. The mutant PRPF31 iPSC-RPE cells recapitulate the cellular phenotype associated with the PRPF31 pathology, including defective cell structure, diminished phagocytic function, defects in ciliogenesis, and compromised barrier function. Treatment of the mutant PRPF31 iPSC-RPE cells with AAV-PRPF31 restored normal phagocytosis and cilia formation, and it partially restored structure and barrier function. These results suggest that AAV-based gene therapy targeting RPE cells holds therapeutic promise for patients with PRPF31-related RP. Retinitis pigmentosa (RP) is the most common form of inherited vision loss and is characterized by degeneration of retinal photoreceptor cells and the retinal pigment epithelium (RPE). Mutations in pre-mRNA processing factor 31 (PRPF31) cause dominant RP via haploinsufficiency with incomplete penetrance. There is good evidence that the diverse severity of this disease is a result of differing levels of expression of the wild-type allele among patients. Thus, we hypothesize that PRPF31-related RP will be amenable to treatment by adeno-associated virus (AAV)-mediated gene augmentation therapy. To test this hypothesis, we used induced pluripotent stem cells (iPSCs) with mutations in PRPF31 and differentiated them into RPE cells. The mutant PRPF31 iPSC-RPE cells recapitulate the cellular phenotype associated with the PRPF31 pathology, including defective cell structure, diminished phagocytic function, defects in ciliogenesis, and compromised barrier function. Treatment of the mutant PRPF31 iPSC-RPE cells with AAV-PRPF31 restored normal phagocytosis and cilia formation, and it partially restored structure and barrier function. These results suggest that AAV-based gene therapy targeting RPE cells holds therapeutic promise for patients with PRPF31-related RP." @default.
• W2984520652 created "2019-11-22" @default.
• W2984520652 creator A5030672894 @default.
• W2984520652 creator A5032539966 @default.
• W2984520652 creator A5048366850 @default.
• W2984520652 creator A5064501640 @default.
• W2984520652 creator A5074590878 @default.
• W2984520652 creator A5086244647 @default.
• W2984520652 date "2019-12-01" @default.
• W2984520652 modified "2023-10-05" @default.
• W2984520652 title "AAV-Mediated Gene Augmentation Therapy Restores Critical Functions in Mutant PRPF31+/− iPSC-Derived RPE Cells" @default.
• W2984520652 cites W1488206823 @default.
• W2984520652 cites W1503104403 @default.
• W2984520652 cites W1518729035 @default.
• W2984520652 cites W1966156338 @default.
• W2984520652 cites W1967387655 @default.
• W2984520652 cites W1977709885 @default.
• W2984520652 cites W1987319020 @default.
• W2984520652 cites W1988485709 @default.
• W2984520652 cites W1992860553 @default.
• W2984520652 cites W1994711951 @default.
• W2984520652 cites W1996493838 @default.
• W2984520652 cites W2014713739 @default.
• W2984520652 cites W2016364569 @default.
• W2984520652 cites W2035534672 @default.
• W2984520652 cites W2047608515 @default.
• W2984520652 cites W2049417498 @default.
• W2984520652 cites W2052450058 @default.
• W2984520652 cites W2072239613 @default.
• W2984520652 cites W2074744546 @default.
• W2984520652 cites W2083729128 @default.
• W2984520652 cites W2085824880 @default.
• W2984520652 cites W2086790354 @default.
• W2984520652 cites W2096173343 @default.
• W2984520652 cites W2099540110 @default.
• W2984520652 cites W2111274886 @default.
• W2984520652 cites W2117239445 @default.
• W2984520652 cites W2121662637 @default.
• W2984520652 cites W2129174402 @default.
• W2984520652 cites W2137222303 @default.
• W2984520652 cites W2141588316 @default.
• W2984520652 cites W2142046859 @default.
• W2984520652 cites W2149738882 @default.
• W2984520652 cites W2151809142 @default.
• W2984520652 cites W2152090260 @default.
• W2984520652 cites W2337020324 @default.
• W2984520652 cites W2405682749 @default.
• W2984520652 cites W2408923606 @default.
• W2984520652 cites W2781905533 @default.
• W2984520652 cites W2783373669 @default.
• W2984520652 cites W2806820493 @default.
• W2984520652 cites W2807198924 @default.
• W2984520652 cites W2890721979 @default.
• W2984520652 cites W2897873128 @default.
• W2984520652 cites W2908402311 @default.
• W2984520652 cites W2949774640 @default.
• W2984520652 doi "https://doi.org/10.1016/j.omtm.2019.10.014" @default.
• W2984520652 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6909184" @default.
• W2984520652 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31890732" @default.
• W2984520652 hasPublicationYear "2019" @default.
• W2984520652 type Work @default.
• W2984520652 sameAs 2984520652 @default.
• W2984520652 citedByCount "26" @default.
• W2984520652 countsByYear W29845206522020 @default.
• W2984520652 countsByYear W29845206522021 @default.
• W2984520652 countsByYear W29845206522022 @default.
• W2984520652 countsByYear W29845206522023 @default.
• W2984520652 crossrefType "journal-article" @default.
• W2984520652 hasAuthorship W2984520652A5030672894 @default.
• W2984520652 hasAuthorship W2984520652A5032539966 @default.
• W2984520652 hasAuthorship W2984520652A5048366850 @default.
• W2984520652 hasAuthorship W2984520652A5064501640 @default.
• W2984520652 hasAuthorship W2984520652A5074590878 @default.
• W2984520652 hasAuthorship W2984520652A5086244647 @default.
• W2984520652 hasBestOaLocation W29845206521 @default.
• W2984520652 hasConcept C100094513 @default.
• W2984520652 hasConcept C104317684 @default.
• W2984520652 hasConcept C107459253 @default.
• W2984520652 hasConcept C127716648 @default.
• W2984520652 hasConcept C145103041 @default.
• W2984520652 hasConcept C169760540 @default.
• W2984520652 hasConcept C195267511 @default.
• W2984520652 hasConcept C200544954 @default.
• W2984520652 hasConcept C2777093970 @default.
• W2984520652 hasConcept C2778024200 @default.
• W2984520652 hasConcept C2780724529 @default.
• W2984520652 hasConcept C2780827179 @default.
• W2984520652 hasConcept C2781040256 @default.
• W2984520652 hasConcept C2781114197 @default.
• W2984520652 hasConcept C54355233 @default.
• W2984520652 hasConcept C55493867 @default.
• W2984520652 hasConcept C68838962 @default.
• W2984520652 hasConcept C86803240 @default.
• W2984520652 hasConcept C95444343 @default.
• W2984520652 hasConceptScore W2984520652C100094513 @default.
• W2984520652 hasConceptScore W2984520652C104317684 @default.
• W2984520652 hasConceptScore W2984520652C107459253 @default.
• W2984520652 hasConceptScore W2984520652C127716648 @default.

• next